Real-World study confirms T-DM1 safety in advanced breast cancer
NCT ID NCT05945927
First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This study observed 178 Chinese patients with HER2-positive advanced breast cancer who received the drug T-DM1 after earlier treatments failed. Researchers tracked side effects and how long the drug kept the cancer from growing in real-world settings. The goal was to confirm the drug's safety and effectiveness outside of controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Hebei University
Baoding, China
-
Affiliated Hospital of Nantong University
Nantong, 226001, China
-
Anhui Province Cancer Hospital
Hefei, 230031, China
-
Anyang Tumor Hosptial
Anyang, 455000, China
-
Beijing Hospital
Beijing, 100730, China
-
Cancer Hospital Affliated to Xinjiang Medical University
Ürümqi, 830011, China
-
Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Center
Shenzhen, 518127, China
-
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, 100021, China
-
China Medical University (CMU) First Affiliated Hospital
Shenyang, 110001, China
-
Dongyang People's Hospital
Jinhua, China
-
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, 710061, China
-
Fujian Cancer Hospital
Fuzhou, 350014, China
-
Guangxi Cancer Hospital of Guangxi Medical University
Nanning, 530021, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Hubei Cancer Hospital
Wuhan, 430079, China
-
Jiangmen Central Hospital
Jiangmen, 529030, China
-
Nanjing Gulou Hospital
Nanjing, China
-
Ningbo No.2 Hospital
Ningbo, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, 030013, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, 510120, China
-
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, China
-
The First Affiliated Hospital Of Shandong First Medical University
Jinan, 250014, China
-
The Third Hospital of Nanchang
Nanchang, 330009, China
-
Tianjin Cancer Hospital
Tianjin, China
-
Union Hospital of Tongji Medical College, Dept. of Cancer Center
Wuhan, 430023, China
-
Weifang People's Hospital
Weifang, 261041, China
-
West China Hospital of Sichuan University
Chengdu, 610041, China
-
Yibin Second People's Hospital
Yibin, China
-
Zhejiang Cancer Hospital
Zhejiang, 310022, China
-
the First Hospital of Jilin University
Changchun, 130021, China
Conditions
Explore the condition pages connected to this study.